Calidi Biotherapeutics ups ATM offering capacity to $11.2M, adds $6.1M

Calidi Biotherapeutics, Inc.

Increased maximum ATM offering from $5.1M to $11.2M under existing sales agreement.
Filed prospectus supplement for $6.1M of common stock; $5.0M already previously sold.
Move provides additional equity capital for company's ongoing operations.

item 8.01 item 9.01

Calidi Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-004887

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.